Windtree reports positive istaroxime interim data in SCAI Stage C cardiogenic shock; plans global Phase 3

WINDTREE THERAPEUTICS INC /DE/

Interim analysis of first 20 patients in SEISMiC C Phase 2 study: no new safety signals, hemodynamic improvements consistent with prior trials.
Istaroxime was added to existing inotropes/vasopressors; no excess arrhythmias observed despite greater illness severity.
Company cites data as instrumental for moving istaroxime to a global Phase 3 program in heart failure and cardiogenic shock.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.